# Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET

> **NCT04385992** · PHASE2 · COMPLETED · sponsor: **IRCCS San Raffaele** · enrollment: 31 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** 177Lu-Dotatate

## Key facts

- **NCT ID:** NCT04385992
- **Lead sponsor:** IRCCS San Raffaele
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-09
- **Primary completion:** 2023-01-25
- **Final completion:** 2023-06-26
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2023-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04385992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04385992, "Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04385992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*